Journal

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study

Read time: 1 mins

Published:15th May 2018

Author: Freedman MS, Morawski J, Thangavelu K.

Source: Multiple Sclerosis Journal – Experimental, Translational and Clinical

Availability: Free full text

Ref.:Mult Scler J Exp Transl Clin. 2018;4(2):2055217318775236.

DOI:10.1177/2055217318775236

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study

Patients enrolled in the phase 3 TOWER study (NCT00751881) of teriflunomide had variable treatment durations (48-173 weeks). This has led to challenges when interpreting results in the context of other phase 3 trials of disease-modifying therapies for multiple sclerosis, which typically have a fixed 2-year duration.

This communication reports clinical outcomes in TOWER over a fixed 2-year period. Reductions in annualised relapse rates and 12-week confirmed disability worsening associated with teriflunomide were comparable between overall intent-to-treat and fixed 2-year study populations in TOWER. Consistency in outcomes supports the inclusion of TOWER data in comparative analyses with other disease-modifying therapies.

Read abstract on library site Access full article